Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01185340
Registration number
NCT01185340
Ethics application status
Date submitted
18/08/2010
Date registered
19/08/2010
Date last updated
27/04/2018
Titles & IDs
Public title
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
Query!
Scientific title
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Query!
Secondary ID [1]
0
0
H9P-MC-LNBR
Query!
Secondary ID [2]
0
0
12183
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - LY2216684
Treatment: Drugs - Placebo
Treatment: Drugs - SSRI
Experimental: LY2216684 + SSRI - LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.
For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.
During the 1-week abrupt DC Phase, participants maintained their SSRI treatment.
Placebo Comparator: Placebo + SSRI - Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.
During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.
During the 1-week abrupt DC Phase, participants maintained their SSRI treatment.
Treatment: Drugs: LY2216684
Treatment: Drugs: Placebo
Treatment: Drugs: SSRI
Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Query!
Assessment method [1]
0
0
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [1]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [1]
0
0
Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score
Query!
Assessment method [1]
0
0
The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (Item 1), social (Item 2), and family life (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. The Global Functional Impairment Score is the sum of the 3 items, and scores ranged from 0 to 30 with higher values indicating greater disruption in the participant's work life (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [1]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [2]
0
0
Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score
Query!
Assessment method [2]
0
0
The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The impact subscale score was derived by taking the mean of Items 7 through 13 (applicable items only). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. The FAsD impact subscale score ranges from 1 to 5. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Query!
Timepoint [2]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [3]
0
0
Probability of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 at Week 8
Query!
Assessment method [3]
0
0
A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 was defined as remission criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of remission at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.
Query!
Timepoint [3]
0
0
8 weeks
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of Less Than or Equal to 10 for at Least 2 Consecutive Measurements, Including the Participant's Last Measurement
Query!
Assessment method [4]
0
0
A Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to 10 for at least 2 consecutive measurements, including the participant's last measurement was defined as remission criteria at last 2 consecutive visits. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Percentage of participants was calculated by dividing the number of participants who meet criteria for remission at last 2 consecutive visits by the total number of participants analyzed, multiplied by 100%.
Query!
Timepoint [4]
0
0
Randomization up to 8 weeks
Query!
Secondary outcome [5]
0
0
Change From Randomization to Week 8 in Hospital and Anxiety and Depression Scale (HADS) Anxiety Subscale Score
Query!
Assessment method [5]
0
0
The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Query!
Timepoint [5]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [6]
0
0
Probability of Participants Who Have a Greater Than or Equal to 50 Percent Improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8
Query!
Assessment method [6]
0
0
A greater than or equal to 50 percent improvement (that is, a decrease from baseline) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score was defined as response criteria. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). A categorical repeated measures analysis modeled the probability of response at each visit, and the estimated probabilities were adjusted for treatment, visit, baseline MADRS total score, and treatment-by-visit.
Query!
Timepoint [6]
0
0
8 weeks
Query!
Secondary outcome [7]
0
0
Change From Randomization to Week 8 in The Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score
Query!
Assessment method [7]
0
0
The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale (0-3), giving maximum scores of 21 for anxiety and depression subscale. Scores of 11 or more on either subscale were considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 represent 'normal'. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline subscale score, treatment-by-visit, and baseline subscale score-by-visit.
Query!
Timepoint [7]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [8]
0
0
Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Individual Items
Query!
Assessment method [8]
0
0
The Montgomery-Asberg Depression Rating Scale (MADRS) is a rating scale for severity of depressive mood symptoms. The MADRS had a 10-item checklist. Items were rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit and baseline item score-by-visit.
Query!
Timepoint [8]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [9]
0
0
Change From Randomization to Week 8 in Clinical Global Impressions of Severity (CGI-S)
Query!
Assessment method [9]
0
0
Clinical Global Impression - Severity (CGI-S) measures severity of depression at the time of assessment compared with the start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [9]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [10]
0
0
Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Average Score and Experience Subscale Score
Query!
Assessment method [10]
0
0
The Fatigue Associated with Depression (FAsD) is a participant-rated scale with a total of 13 items. Six of the 13 items ask how often participants experience different aspects of fatigue with responses from 1 (never) to 5 (always). Seven of the 13 items ask how often fatigue impacts various aspects of the participant's lives with responses from 1 (not at all) to 5 (very much). The experience subscale score was derived by taking the mean of Items 1 through 6, and the average score was the mean of Items 1 through 13 (derived by taking the mean of all applicable items for each participant). Item 12 applied only to participants with a spouse or significant other, and Item 13 applied to participants who had a job or who went to school. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [10]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [11]
0
0
Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Items
Query!
Assessment method [11]
0
0
The Sheehan Disability Scale (SDS) was completed by the participant and used to assess the effect of the participant's symptoms on their work (work/school impairment score), social life (social life/leisure activities impairment score), and family life (family life/home responsibilities impairment score). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline item score, treatment-by-visit, and baseline item score-by-visit.
Query!
Timepoint [11]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [12]
0
0
Change From Randomization to Week 8 in the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)
Query!
Assessment method [12]
0
0
The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) is a self-administered, 16-item questionnaire measuring degree of enjoyment and satisfaction experienced in various areas of daily life during the past week on a 5-point Likert scale (1=very poor and 5=very good). The total raw score is the sum of Items 1 to 14 and ranges from 14 to 70. The raw scores are converted to and expressed as the percentage of the maximum possible score. Higher scores indicate higher levels of enjoyment/satisfaction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [12]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [13]
0
0
Change From Randomization to Week 8 in the EuroQol Questionnaire-5 Dimension (EQ-5D)
Query!
Assessment method [13]
0
0
The EQ-5D Visual Analog Scale is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score is self-reported using a visual analogue scale, marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [13]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Treatment-emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Query!
Assessment method [14]
0
0
The Columbia-Suicide Severity Rating Scale (C-SSRS) captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation was defined as a "yes" answer to any 1 of 5 suicidal ideation questions, which included a wish to be dead and 4 different categories of active suicidal ideation. Suicidal behavior was defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation and behavior are defined as treatment-emergent (TE) if not present at baseline. Percentage of participants was calculated by dividing the number of participants with suicide-related TE events by the total number of participants at risk, multiplied by 100%. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.
Query!
Timepoint [14]
0
0
Randomization up to 8 weeks
Query!
Secondary outcome [15]
0
0
Change From Randomization to Week 8 in Arizona Sexual Experiences (ASEX) Scale
Query!
Assessment method [15]
0
0
The Arizona Sexual Experiences (ASEX) scale was used to assess sexual functioning in both males and females. The ASEX total score for the male and female version was calculated as the sum of the responses (rated from 1 [extremely] to 6 [no/never]) of the 5 items of the ASEX scale. Total scores ranged from 5 to 30, with higher scores indicating greater sexual dysfunction. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [15]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [16]
0
0
Change From Randomization to Week 8 in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)
Query!
Assessment method [16]
0
0
The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) is a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent). Total scores ranged from 7 to 42. Higher scores indicate greater disease severity. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Query!
Timepoint [16]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [17]
0
0
Change From Randomization to Week 8 in Blood Pressure
Query!
Assessment method [17]
0
0
Blood pressure measurements were collected when the participant was in a sitting position. Three measurements of sitting blood pressure collected at approximately 1-minute intervals at every visit were averaged and used as the value for the visit. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.
Query!
Timepoint [17]
0
0
Randomization, 8 weeks
Query!
Secondary outcome [18]
0
0
Change From Randomization to Week 8 in Pulse Rate
Query!
Assessment method [18]
0
0
Pulse measurements were collected when the participant was in a sitting position. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline value, treatment-by-visit, and baseline value-by-visit.
Query!
Timepoint [18]
0
0
Randomization, 8 weeks
Query!
Eligibility
Key inclusion criteria
- Women of child-bearing potential may participate but must test negative for pregnancy
at the time of study entry; both women/men agree to use a reliable method of birth
control
- Are being treated with one of the following selective serotonin reuptake inhibitors
(SSRIs): escitalopram, citalopram, sertraline, fluoxetine, paroxetine, or fluvoxamine;
for at least 6 weeks prior to investigational product dispensing with at least the
last 4 weeks at a stable, optimized dose
- Drug and dosage should be within the labeling guidelines for the specific country
- Meet criteria for major depressive disorder (MDD), as defined by Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision® (DSM-IV-TR)
criteria
- Meet criteria for partial response, as defined by investigator's opinion that the
participant has experienced a minimal clinically meaningful improvement with SSRI
- Have a GRID 17-Item Hamilton Depression Rating Scale (GRID-HAMD17) total score greater
than or equal to 16 at screening
- Have less than or equal to 75% improvement on the current SSRI at screening determined
by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire
(MGH-ATRQ)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have had or currently have any additional ongoing DSM-IV-TR Axis 1 condition other
than major depression within 1 year of screening
- Have had any anxiety disorder that was considered a primary diagnosis within the past
year (including panic disorder, obsessive-compulsive disorder [OCD], post-traumatic
stress disorder [PTSD], generalized anxiety disorder [GAD], and social phobia, but
excluding specific phobias)
- Have a current or previous diagnosis of a bipolar disorder, schizophrenia, or other
psychotic disorder
- Have a history of substance abuse and/or dependence within the past year (drug
categories defined by DSM-IV-TR), not including caffeine and nicotine
- Have an Axis II disorder that, in the judgment of the investigator, would interfere
with compliance with protocol
- Unstable medical conditions that contraindicate the use of LY2216684
- Have any diagnosed medical condition that could be exacerbated by noradrenergic
agents, including unstable hypertension, unstable heart disease, tachycardia,
tachyarrhythmia, narrow-angled glaucoma, history of urinary hesitancy or retention
- Use of excluded concomitant or psychotropic medication other than SSRI
- Have initiated or discontinued hormone therapy within the 3 months prior to enrollment
- History of treatment-resistant depression as shown by lack of response of the current
depressive episode to 2 or more adequate courses of antidepressant therapy at a
clinically appropriate dose for at least 4 weeks or, in the judgment of the
investigator, the participant has treatment-resistant depression
- Have a lifetime history of vagal nerve stimulation (VNS), transcranial magnetic
stimulation (TMS), or psychosurgery
- Have received electroconvulsive therapy (ECT) in the past year
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1056
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Everton Park
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Spring Hill
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Frankston
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Heidelberg
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Malvern
Query!
Recruitment hospital [6]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
4053 - Everton Park
Query!
Recruitment postcode(s) [2]
0
0
4000 - Spring Hill
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [6]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Louisiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Nebraska
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New Jersey
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Virginia
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Vienna
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Diest
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Liège
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Mont-Godinne
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Bad Saarow
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Berlin
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Bochum
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Cham
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Dresden
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Hattingen
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Leipzig
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Munich
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Nürnberg
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Prien
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Schwerin
Query!
Country [26]
0
0
Sweden
Query!
State/province [26]
0
0
Goteborg
Query!
Country [27]
0
0
Sweden
Query!
State/province [27]
0
0
Lund
Query!
Country [28]
0
0
Sweden
Query!
State/province [28]
0
0
Malmo
Query!
Country [29]
0
0
Sweden
Query!
State/province [29]
0
0
Solna
Query!
Country [30]
0
0
Sweden
Query!
State/province [30]
0
0
Stockholm
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
East Sussex
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Scotland
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Chesterfield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18
mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of
participants with major depressive disorder (MDD) who are partial responders to their
selective serotonin reuptake inhibitor (SSRI) treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01185340
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01185340
Download to PDF